Drug
ocrelizumab
Marketed as OCREVUS.
Generic name
ocrelizumab
Brand names
OCREVUS
First FDA approval
2017-03-28
Patient assistance program
Genentech Patient Foundation
FDA approval history
| FDA ID | Brand | Approval date | Manufacturer |
|---|---|---|---|
| BLA761053 | OCREVUS | 2017-03-28 | GENENTECH INC |
Manufacturers
GENENTECH INC
Common denial patterns
- Site-of-care reduction (home infusion vs hospital)
- Step therapy
Specific notes
Brand: Ocrevus. First FDA-approved DMT for primary progressive MS.
Manufacturer patient assistance
Genentech Patient Foundation: https://www.ocrevus.com
Frequently asked questions
Why does insurance commonly deny ocrelizumab?
Site-of-care reduction (home infusion vs hospital); Step therapy.
When was ocrelizumab FDA approved?
Earliest FDA approval on record: 2017-03-28.
What brand names are sold as ocrelizumab?
OCREVUS.
Is there a patient assistance program for ocrelizumab?
Yes — Genentech Patient Foundation at https://www.ocrevus.com.
What's specific to ocrelizumab?
Brand: Ocrevus. First FDA-approved DMT for primary progressive MS.
Sources
Appeal a ocrelizumab denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com